Table of Contents Chapter 1 Overview of Gastrointestinal Therapeutics 1.1 Definition of Gastrointestinal Therapeutics in This Report 1.2 Commercial Types of Gastrointestinal Therapeutics 1.2.1 Tablets 1.2.2 Injection 1.3 Downstream Application of Gastrointestinal Therapeutics 1.3.1 IBD 1.3.2 Irritable Bowel Syndrome (IBS) 1.3.3 Other 1.4 Development History of Gastrointestinal Therapeutics 1.5 Market Status and Trend of Gastrointestinal Therapeutics 2013-2023 1.5.1 EMEA Gastrointestinal Therapeutics Market Status and Trend 2013-2023 1.5.2 Regional Gastrointestinal Therapeutics Market Status and Trend 2013-2023 Chapter 2 EMEA Market Status and Forecast by Regions 2.1 Market Status of Gastrointestinal Therapeutics in EMEA 2013-2017 2.2 Consumption Market of Gastrointestinal Therapeutics in EMEA by Regions 2.2.1 Consumption Volume of Gastrointestinal Therapeutics in EMEA by Regions 2.2.2 Revenue of Gastrointestinal Therapeutics in EMEA by Regions 2.3 Market Analysis of Gastrointestinal Therapeutics in EMEA by Regions 2.3.1 Market Analysis of Gastrointestinal Therapeutics in Europe 2013-2017 2.3.2 Market Analysis of Gastrointestinal Therapeutics in Middle East 2013-2017 2.3.3 Market Analysis of Gastrointestinal Therapeutics in Africa 2013-2017 2.4 Market Development Forecast of Gastrointestinal Therapeutics in EMEA 2018-2023 2.4.1 Market Development Forecast of Gastrointestinal Therapeutics in EMEA 2018-2023 2.4.2 Market Development Forecast of Gastrointestinal Therapeutics by Regions 2018-2023 Chapter 3 EMEA Market Status and Forecast by Types 3.1 Whole EMEA Market Status by Types 3.1.1 Consumption Volume of Gastrointestinal Therapeutics in EMEA by Types 3.1.2 Revenue of Gastrointestinal Therapeutics in EMEA by Types 3.2 EMEA Market Status by Types in Major Countries 3.2.1 Market Status by Types in Europe 3.2.2 Market Status by Types in Middle East 3.2.3 Market Status by Types in Africa 3.3 Market Forecast of Gastrointestinal Therapeutics in EMEA by Types Chapter 4 EMEA Market Status and Forecast by Downstream Industry 4.1 Demand Volume of Gastrointestinal Therapeutics in EMEA by Downstream Industry 4.2 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Major Countries 4.2.1 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Europe 4.2.2 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Middle East 4.2.3 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Africa 4.3 Market Forecast of Gastrointestinal Therapeutics in EMEA by Downstream Industry Chapter 5 Market Driving Factor Analysis of Gastrointestinal Therapeutics 5.1 EMEA Economy Situation and Trend Overview 5.2 Gastrointestinal Therapeutics Downstream Industry Situation and Trend Overview Chapter 6 Gastrointestinal Therapeutics Market Competition Status by Major Players in EMEA 6.1 Sales Volume of Gastrointestinal Therapeutics in EMEA by Major Players 6.2 Revenue of Gastrointestinal Therapeutics in EMEA by Major Players 6.3 Basic Information of Gastrointestinal Therapeutics by Major Players 6.3.1 Headquarters Location and Established Time of Gastrointestinal Therapeutics Major Players 6.3.2 Employees and Revenue Level of Gastrointestinal Therapeutics Major Players 6.4 Market Competition News and Trend 6.4.1 Merger, Consolidation or Acquisition News 6.4.2 Investment or Disinvestment News 6.4.3 New Product Development and Launch Chapter 7 Gastrointestinal Therapeutics Major Manufacturers Introduction and Market Data 7.1 Johnson & Johnson 7.1.1 Company profile 7.1.2 Representative Gastrointestinal Therapeutics Product 7.1.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Johnson & Johnson 7.2 AbbVie 7.2.1 Company profile 7.2.2 Representative Gastrointestinal Therapeutics Product 7.2.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie 7.3 Allergan 7.3.1 Company profile 7.3.2 Representative Gastrointestinal Therapeutics Product 7.3.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Allergan 7.4 Takeda 7.4.1 Company profile 7.4.2 Representative Gastrointestinal Therapeutics Product 7.4.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Takeda 7.5 Novartis 7.5.1 Company profile 7.5.2 Representative Gastrointestinal Therapeutics Product 7.5.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Novartis 7.6 Pfizer 7.6.1 Company profile 7.6.2 Representative Gastrointestinal Therapeutics Product 7.6.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Pfizer 7.7 GlaxoSmithKline 7.7.1 Company profile 7.7.2 Representative Gastrointestinal Therapeutics Product 7.7.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of GlaxoSmithKline 7.8 Merck 7.8.1 Company profile 7.8.2 Representative Gastrointestinal Therapeutics Product 7.8.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Merck 7.9 UCB (Belgium) 7.9.1 Company profile 7.9.2 Representative Gastrointestinal Therapeutics Product 7.9.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of UCB (Belgium) 7.10 F. Hoffmann-La Roche 7.10.1 Company profile 7.10.2 Representative Gastrointestinal Therapeutics Product 7.10.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche 7.11 Eli Lilly 7.11.1 Company profile 7.11.2 Representative Gastrointestinal Therapeutics Product 7.11.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lilly 7.12 AstraZeneca 7.12.1 Company profile 7.12.2 Representative Gastrointestinal Therapeutics Product 7.12.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca 7.13 Procter & Gamble 7.13.1 Company profile 7.13.2 Representative Gastrointestinal Therapeutics Product 7.13.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Procter & Gamble 7.14 Eisai 7.14.1 Company profile 7.14.2 Representative Gastrointestinal Therapeutics Product 7.14.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Eisai 7.15 Shire Pharmaceuticals 7.15.1 Company profile 7.15.2 Representative Gastrointestinal Therapeutics Product 7.15.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Shire Pharmaceuticals 7.16 Ferring Pharmaceuticals 7.17 Kyowa Hakko Kirin 7.18 Salix Pharmaceuticals 7.19 Ono Pharmaceutical 7.20 TSD Japan 7.21 RedHill Biopharma 7.22 Kaken Pharmaceutical 7.23 Amgen 7.24 Synergy Pharmaceuticals 7.25 Ajinomoto 7.26 Kissei Pharmaceutical 7.27 Hutchison Medi Pharma Chapter 8 Upstream and Downstream Market Analysis of Gastrointestinal Therapeutics 8.1 Industry Chain of Gastrointestinal Therapeutics 8.2 Upstream Market and Representative Companies Analysis 8.3 Downstream Market and Representative Companies Analysis Chapter 9 Cost and Gross Margin Analysis of Gastrointestinal Therapeutics 9.1 Cost Structure Analysis of Gastrointestinal Therapeutics 9.2 Raw Materials Cost Analysis of Gastrointestinal Therapeutics 9.3 Labor Cost Analysis of Gastrointestinal Therapeutics 9.4 Manufacturing Expenses Analysis of Gastrointestinal Therapeutics Chapter 10 Marketing Status Analysis of Gastrointestinal Therapeutics 10.1 Marketing Channel 10.1.1 Direct Marketing 10.1.2 Indirect Marketing 10.1.3 Marketing Channel Development Trend 10.2 Market Positioning 10.2.1 Pricing Strategy 10.2.2 Brand Strategy 10.2.3 Target Client 10.3 Distributors/Traders List Chapter 11 Report Conclusion Chapter 12 Research Methodology and Reference 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Reference

List of Tables Table Advantage and Disadvantage of Tablets Table Advantage and Disadvantage of Injection Table Consumption Volume of Gastrointestinal Therapeutics in EMEA by Regions 2013-2017 Table Revenue of Gastrointestinal Therapeutics in EMEA by Regions 2013-2017 Table Consumption Volume of Gastrointestinal Therapeutics in EMEA by Regions 2018-2023 Table Revenue of Gastrointestinal Therapeutics in EMEA by Regions 2018-2023 Table Consumption Volume of Gastrointestinal Therapeutics in EMEA by Types 2013-2017 Table Revenue of Gastrointestinal Therapeutics in EMEA by Types 2013-2017 Table Consumption Volume of Gastrointestinal Therapeutics by Types in Europe 2013-2017 Table Consumption Volume of Gastrointestinal Therapeutics by Types in Middle East 2013-2017 Table Consumption Volume of Gastrointestinal Therapeutics by Types in Africa 2013-2017 Table Consumption Volume Forecast of Gastrointestinal Therapeutics in EMEA by Types 2018-2023 Table Revenue Forecast of Gastrointestinal Therapeutics in EMEA by Types 2018-2023 Table Demand Volume of Gastrointestinal Therapeutics in EMEA by Downstream Industry 2013-2017 Table Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Europe 2013-2017 Table Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Middle East 2013-2017 Table Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Africa 2013-2017 Table Demand Volume Forecast of Gastrointestinal Therapeutics in EMEA by Downstream Industry 2018-2023 Table Sales Volume of Gastrointestinal Therapeutics in EMEA by Major Players 2013-2017 Table Revenue of Gastrointestinal Therapeutics in EMEA by Major Players 2013-2017 Table Headquarters Location and Established Time of Gastrointestinal Therapeutics Major Players Table Employees and Revenue Level of Gastrointestinal Therapeutics Major Players Table Representative Gastrointestinal Therapeutics Product One of Johnson & Johnson Table Representative Gastrointestinal Therapeutics Product Two of Johnson & Johnson Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Johnson & Johnson 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of AbbVie Table Representative Gastrointestinal Therapeutics Product Two of AbbVie Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of Allergan Table Representative Gastrointestinal Therapeutics Product Two of Allergan Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Allergan 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of Takeda Table Representative Gastrointestinal Therapeutics Product Two of Takeda Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Takeda 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of Novartis Table Representative Gastrointestinal Therapeutics Product Two of Novartis Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Novartis 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of Pfizer Table Representative Gastrointestinal Therapeutics Product Two of Pfizer Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Pfizer 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of GlaxoSmithKline Table Representative Gastrointestinal Therapeutics Product Two of GlaxoSmithKline Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of GlaxoSmithKline 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of Merck Table Representative Gastrointestinal Therapeutics Product Two of Merck Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Merck 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of UCB (Belgium) Table Representative Gastrointestinal Therapeutics Product Two of UCB (Belgium) Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of UCB (Belgium) 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of F. Hoffmann-La Roche Table Representative Gastrointestinal Therapeutics Product Two of F. Hoffmann-La Roche Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of Eli Lilly Table Representative Gastrointestinal Therapeutics Product Two of Eli Lilly Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lilly 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of AstraZeneca Table Representative Gastrointestinal Therapeutics Product Two of AstraZeneca Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of Procter & Gamble Table Representative Gastrointestinal Therapeutics Product Two of Procter & Gamble Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Procter & Gamble 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of Eisai Table Representative Gastrointestinal Therapeutics Product Two of Eisai Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Eisai 2013-2017 Table Representative Gastrointestinal Therapeutics Product One of Shire Pharmaceuticals Table Representative Gastrointestinal Therapeutics Product Two of Shire Pharmaceuticals Table Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Shire Pharmaceuticals 2013-2017